- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| INTENSITY THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 20.08. | Benchmark lowers Intensity Therapeutics stock price target to $1.50 on dilution | 2 | Investing.com | ||
| 12.08. | INTENSITY THERAPEUTICS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 12.08. | Brookline Capital upgrades Intensity Therapeutics stock rating to Buy | 3 | Investing.com | ||
| 12.08. | Intensity Therapeutics regains compliance with Nasdaq requirement | 2 | Seeking Alpha | ||
| 12.08. | Intensity Therapeutics Inc.: Intensity Therapeutics, Inc. Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement | 118 | PR Newswire | SHELTON, Conn., Aug. 12, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or "the Company"), a late-stage clinical biotechnology... ► Artikel lesen | |
| 08.08. | Intensity Therapeutics GAAP EPS of -$0.13 | 1 | Seeking Alpha | ||
| 07.08. | Intensity Therapeutics Inc.: Intensity Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update | 54 | PR Newswire | Over $11 million raised since the beginning of 2Q 2025
Cash runway extended into the second half of 2026
In the INVINCIBLE-4 Study, patients receiving INT230-6... ► Artikel lesen | |
| 07.08. | INTENSITY THERAPEUTICS, INC. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 04.08. | INTENSITY THERAPEUTICS, INC. - 8-K, Current Report | 3 | SEC Filings | ||
| 04.08. | Intensity Therapeutics raises $6.6M via at-the-market offering | 2 | Seeking Alpha | ||
| 18.07. | Intensity Therapeutics: Aktionäre bestätigen Direktor und Wirtschaftsprüfer | 2 | Investing.com Deutsch | ||
| 18.07. | INTENSITY THERAPEUTICS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 30.06. | Intensity Therapeutics: INT230-6 Achieves Complete Responses In Murine Models Of MPNST | 1 | RTTNews | ||
| 30.06. | Intensity Therapeutics Inc.: Intensity Therapeutics, Inc. Announces that INT230-6 Achieved 100% Complete Response Rate in Preclinical Models of Malignant Peripheral Nerve Sheath Tumors (MPNST) | 120 | PR Newswire | SHELTON, Conn., June 30, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or "the Company"), a late-stage clinical biotechnology... ► Artikel lesen | |
| 27.06. | INTENSITY THERAPEUTICS, INC. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 11.06. | Intensity Therapeutics shares plummet on proposed public offering | 3 | Seeking Alpha | ||
| 11.06. | Intensity Therapeutics kündigt öffentliches Angebot von Stammaktien an | 3 | Investing.com Deutsch | ||
| 11.06. | Intensity Therapeutics Inc.: Intensity Therapeutics, Inc. Announces Patients Receiving INT230-6 Prior to the Start of Standard-of-Care May Achieve High Levels of Tumor Necrosis in the Ongoing Randomized Controlled Phase ... | 302 | PR Newswire | SHELTON, Conn., June 11, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or the "Company"), a late-stage clinical biotechnology company focused on the... ► Artikel lesen | |
| 06.06. | INTENSITY THERAPEUTICS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 20.05. | INTENSITY THERAPEUTICS, INC. - 8-K, Current Report | 4 | SEC Filings |
1 2 Weiter >>
37 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 86,10 | -0,46 % | BioNTech Aktie: Kurssturz? - Circus, Commerzbank, Evotec, Puma und SFC Energy im Marktbericht Börse Frankfurt | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| NOVAVAX | 6,536 | +0,69 % | Novavax Aktie: BRUTALE PROGNOSE zwingt Anleger zum Handeln. So sollten Sie HEUTE reagieren! | ||
| CRISPR THERAPEUTICS | 45,600 | +0,88 % | 1 Reason Every Investor Should Know About CRISPR Therapeutics (CRSP) | ||
| EDITAS MEDICINE | 2,208 | +3,86 % | Editas Medicine, Inc.: Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate | EDIT-401 achieved ~90% mean LDL-C reduction with single dose in non-human primates EDIT-401 on track for human proof-of-concept data by end of 2026 Strong cash position with operational runway into... ► Artikel lesen | |
| GINKGO BIOWORKS | 9,900 | +4,76 % | Ginkgo Bioworks Holdings, Inc. - 8-K, Current Report | ||
| NOVOCURE | 10,325 | -1,43 % | Novocure Announces Upcoming Investor Events | Novocure (NASDAQ: NVCR) announced today that management will participate in three upcoming investor events.
2025 Wells Fargo Healthcare Conference, September 4, 2025: Ashley Cordova, Chief... ► Artikel lesen | |
| ADAPTIMMUNE THERAPEUTICS | 0,049 | 0,00 % | Adaptimmune Therapeutics PLC - 8-K, Current Report | ||
| ADVERUM BIOTECHNOLOGIES | 2,580 | -0,77 % | Adverum Biotechnologies, Inc.: Adverum Biotechnologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | REDWOOD CITY, Calif., June 05, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM) today announced that the Compensation Committee of Adverum's Board of Directors granted inducement... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 29,480 | +2,15 % | Jefferies raises Mineralys Therapeutics stock price target to $26 from $15 | ||
| QIAGEN | 40,105 | -0,21 % | Qiagen: Neue Wandelschuldverschreibungen über 750 Mio. USD | Qiagen hat die Ausgabe von Wandelschuldverschreibungen mit Netto-Aktienausgleich beschlossen. Das Volumen beläuft sich auf 750 Millionen US-Dollar, die Stückelung beträgt jeweils 200.000 US-Dollar.... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 46,730 | -1,06 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights | Aligned with FDA on del-brax accelerated and full approval pathways for FSHD, reported positive topline data from Phase 1/2 FORTITUDE trial, and initiated global... ► Artikel lesen | |
| EVOTEC | 5,832 | +0,73 % | SONDERMELDUNG AM MITTWOCH: Evotec-Aktionäre müssen heute dringend handeln, denn sonst ist alles aus und vorbei! | ||
| BEAM THERAPEUTICS | 18,525 | +13,58 % | Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease | CAMBRIDGE, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that... ► Artikel lesen | |
| ARS PHARMACEUTICALS | 11,060 | -0,41 % | ARS Pharma drops 9% as Lupin files application for generic neffy | ||
| RECURSION PHARMACEUTICALS | 4,670 | +0,21 % | If You'd Invested $1,000 in Recursion Pharmaceuticals 4 Years Ago, Here's How Much You'd Have Today |
INTENSITY THERAPEUTICS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,002 (+0,58 %) liegt der Kurs bei 0,277 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu INTENSITY THERAPEUTICS INC finden Sie auf Wallstreet Online.